Waldiomycin, a novel WalK-histidine kinase inhibitor from Streptomyces sp. MK844-mF10

49Citations
Citations of this article
61Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

WalK, a histidine kinase, and WalR, a response regulator, make up a two-component signal transduction system that is indispensable for the cell-wall metabolism of low GC Gram-positive bacteria. WalK inhibitors are likely to show bactericidal effects against methicillin-resistant Staphylococcus aureus. We discovered a new WalK inhibitor, designated waldiomycin, by screening metabolites from actinomycetes. Waldiomycin belongs to the family of angucycline antibiotics and is structurally related to dioxamycin. Waldiomycin inhibits WalK from S. aureus and Bacillus subtilis at IC50 s 8.8 and 10.2 μM, respectively, and shows antibacterial activity with MICs ranging from 4 to 8 μg ml-1 against methicillin-resistant S. aureus and B. subtilis. © 2013 Japan Antibiotics Research Association All rights reserved.

Cite

CITATION STYLE

APA

Igarashi, M., Watanabe, T., Hashida, T., Umekita, M., Hatano, M., Yanagida, Y., … Nomoto, A. (2013). Waldiomycin, a novel WalK-histidine kinase inhibitor from Streptomyces sp. MK844-mF10. Journal of Antibiotics, 66(8), 459–464. https://doi.org/10.1038/ja.2013.33

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free